Alzheimer’s survey reveals nearly half of UK adults believe a cure will be developed in their lifetime
Sep 18, 2018
From a sample of 1,000 UK adults, 66% are worried that they may develop Alzheimer’s disease and 89% believe the solution to tackling diseases lies in medical research1
82% are willing to take part in medical research but three-quarters (76%) have no idea how to get involved1
This World Alzheimer’s Month, in association with Alzheimer’s Disease International, Novartis, Amgen and Banner Alzheimer’s Institute are raising awareness about how to get involved in Alzheimer’s research
Frimley, UK, September 18, 2018 – Novartis, Amgen and Banner Alzheimer’s Institute (BAI), in association with Alzheimer’s Disease International (ADI), today announced results from an online survey investigating perceptions of Alzheimer’s disease. Findings show that most adults (66%) in the UK are worried that they may develop Alzheimer’s, but nearly half (47%) believe it is likely a cure will be developed in their lifetime.1 This World Alzheimer’s Month, Novartis, Amgen, BAI and ADI are raising awareness about how volunteers can take part in clinical studies to benefit Alzheimer’s research, potentially themselves and future generations.
Alzheimer’s is the leading cause of dementia, which affects 850,000 people in the UK.2 This number is expected to increase to over one million by 2025 and over two million by 2050.2 The survey of more than 1,000 adults in the UK revealed that 89% believe the solution to tackling diseases lies in medical research and 82% are willing to participate.1 However, 76% have no idea how to get involved in medical research.1
“At present, there is no cure and limited treatment options for Alzheimer’s, but this survey clearly shows that people are willing to participate in research to help treat and to hopefully find a cure,” said Paola Barbarino, Chief Executive Officer at ADI. “We need to demystify and remove awareness barriers to participation in medical research, making all suitable candidates aware of how they can get involved.”
In the UK, more than 20 clinical studies are recruiting in Alzheimer’s.3 However, slow enrolment is a costly and common obstacle that undermines medical research.4 There is a need for more people to volunteer to advance scientific discovery. “The results from this survey clearly demonstrate the need to raise awareness about clinical studies globally,” said Pierre N. Tariot, MD, director of BAI and co-director of the Alzheimer’s Prevention Initiative (API). “Aside from funding, the greatest challenge in finding a way to treat, slow, or prevent Alzheimer’s is the recruitment and retention of study participants. Scientists are making great progress in the fight against this disease, but an estimated 80% of studies fail to meet recruitment goals on time, which delays critically important research.”
September 2018 marks the 7th World Alzheimer's Month and represents a chance for people to raise awareness, fundraise and find out more about how they can participate in research. In addition to the survey results, ADI will also launch their World Alzheimer Report 2018 entitled The state of the art of dementia research: new frontiers, which looks at the hopes and aspirations, the barriers and enablers to improving dementia research globally. More information on the report can be found here: www.alz.co.uk/worldreport2018.
“With one adult developing Alzheimer’s every three minutes in the UK, it is vital we focus on research efforts to prevent or delay this disease,” said Dr Mark Toms MBChB, Chief Scientific Officer at Novartis UK. “This survey has clearly identified that greater awareness is needed for people to get involved in clinical research. For over 70 years we’ve been serving patients in Neuroscience and are committed to reimagining Alzheimer’s care for the future.”
Information about clinical studies is widely available online and from local patient advocacy groups. Details on how to become involved in Alzheimer's research can be found by visiting the Join Dementia Research website www.joindementiaresearch.nihr.ac.uk and details of all current UK Alzheimer’s clinical studies can be found on the ClinicalTrials.gov study database, under the search criteria 'Recruiting' ‘Alzheimer Disease’, and ‘United Kingdom’. For studies sponsored by Novartis, please contact the Medical Information Team on 01276 698370 or email: [email protected].
About the survey
The survey was conducted online by The Harris Poll on behalf of Novartis, Amgen and Banner Alzheimer’s Institute, among 1,033 adults 18+ living in the UK. The survey was conducted between July 25 and August 21, 2018. Figures for age by gender, income, education, region, size of household, marital status, and employment status were weighted where necessary to bring them into line with their actual proportions in the population. The UK survey was a part of a larger global survey investigating perceptions of Alzheimer’s disease of over 10,000 adults across 10 countries.
About Amgen and Novartis Neuroscience Collaboration
In August 2015, Novartis entered into a global collaboration with Amgen to develop and commercialize pioneering treatments in the field of migraine and Alzheimer's disease.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
In the UK, Novartis develops, manufactures and markets innovative medicines, devices and diagnostic tests which help improve patient outcomes. Based on four sites across the north and south of England, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis by manufacturing the active pharmaceutical ingredients used worldwide in many medicines. In 2017 Novartis invested almost £30million in R&D and is a leading sponsor of clinical trials in the UK. For more information, please visit www.novartis.co.uk.